Literature DB >> 17060128

13C-methacetin and 13C-galactose breath tests can assess restricted liver function even in early stages of primary biliary cirrhosis.

Julia Holtmeier1, Maria Leuschner, Arne Schneider, Ulrich Leuschner, Wolfgang F Caspary, Barbara Braden.   

Abstract

OBJECTIVE: The 13C-methacetin breath test quantitatively evaluates cytochrome P450-dependent liver function. The 13C-galactose breath test non-invasively measures the galactose oxidation capacity of the liver. The aim of this study was to find out whether these breath tests are sensitive parameters also in non-cirrhotic patients with primary biliary cirrhosis.
MATERIAL AND METHODS: Nineteen patients with early-stage primary biliary cirrhosis (no cirrhotic alterations in the liver biopsy, Ludwig stage I-III) and 20 healthy controls underwent the 13C-methacetin and 13C-galactose breath tests.
RESULTS: Patients with primary biliary cirrhosis metabolized less 13C-methacetin than controls (cumulative recovery within 30 min 7.5+/-2.4% versus 14.0+/-2.6%; p < 0.001). When a cut-off > 9.8% was used for the cumulative recovery after 30 min, the methacetin breath test reached 84.2% sensitivity and 95.0 specificity. In the 13C-galactose breath test, the percentage recovery at 60 min in patients was 3.1+/-1.3%/h, and 6.3+/-1.1%/h in controls (p < 0.001). Using a cut-off > 4.7%/h, the galactose breath test reached 89.5% sensitivity and 95.0 specificity.
CONCLUSIONS: In non-cirrhotic, early-stage, primary biliary cirrhosis the 13C-methacetin breath test and the 13C-galactose breath test reliably indicate decreased liver function. The 13C-galactose breath test can also predict the histological score.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17060128     DOI: 10.1080/00365520600670125

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  7 in total

Review 1.  Clinical utility of 13C-liver-function breath tests for assessment of hepatic function.

Authors:  P Afolabi; M Wright; S A Wootton; A A Jackson
Journal:  Dig Dis Sci       Date:  2012-08-17       Impact factor: 3.199

2.  C-methacetin breath test reproducibility study reveals persistent CYP1A2 stimulation on repeat examinations.

Authors:  Anna Kasicka-Jonderko; Anna Nita; Krzysztof Jonderko; Magdalena Kamińska; Barbara Błońska-Fajfrowska
Journal:  World J Gastroenterol       Date:  2011-12-07       Impact factor: 5.742

3.  Evaluation of the 13C-octanoate breath test as a surrogate marker of liver damage in animal models.

Authors:  Tamar Shalev; Hussein Aeed; Vladimir Sorin; Mark Shahmurov; Elena Didkovsky; Yaron Ilan; Yona Avni; Haim Shirin
Journal:  Dig Dis Sci       Date:  2010-06       Impact factor: 3.199

4.  Diagnostic value of the C methacetin breath test in various stages of chronic liver disease.

Authors:  Hamizah Razlan; Nurhayaty Muhamad Marzuki; Mei-Ling Sharon Tai; Azhar-Shah Shamsul; Tze-Zen Ong; Sanjiv Mahadeva
Journal:  Gastroenterol Res Pract       Date:  2011-06-07       Impact factor: 2.260

Review 5.  (13)CO2 breath tests in non-invasive hepatological diagnosis.

Authors:  Joanna Musialik; Krzysztof Jonderko; Anna Kasicka-Jonderko; Magdalena Buschhaus
Journal:  Prz Gastroenterol       Date:  2015-01-14

6.  (13C)-Methacetin breath test provides evidence of subclinical liver dysfunction linked to fat storage but not lifestyle.

Authors:  Emilio Molina-Molina; Harshitha Shanmugam; Agostino Di Ciaula; Ignazio Grattagliano; Domenica Maria Di Palo; Vincenzo O Palmieri; Piero Portincasa
Journal:  JHEP Rep       Date:  2020-11-04

7.  Hepatobiliary MRI: Signal intensity based assessment of liver function correlated to 13C-Methacetin breath test.

Authors:  Michael Haimerl; Ute Probst; Stefanie Poelsterl; Lukas Beyer; Claudia Fellner; Michael Selgrad; Matthias Hornung; Christian Stroszczynski; Philipp Wiggermann
Journal:  Sci Rep       Date:  2018-06-13       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.